<![CDATA[Preeclampsia and eclampsia remain among the most serious obstetric complications worldwide, contributing significantly to maternal and perinatal morbidity and mortality. This literature review aims to comprehensively examine and synthesize current evidence regarding the therapeutic management of preeclampsia and eclampsia, encompassing both pharmacological and non-pharmacological approaches. A systematic search of electronic databases including PubMed, CINAHL, ScienceDirect, and Cochrane Library was conducted covering publications from 2014 to 2024, yielding 35 articles that met the inclusion criteria. The review identified that antihypertensive therapy, magnesium sulfate administration, and timely delivery remain the cornerstones of management. Labetalol, nifedipine, and hydralazine are the most commonly recommended antihypertensives for acute blood pressure control, while magnesium sulfate is the gold standard for seizure prophylaxis and treatment. Corticosteroids play an important role in fetal lung maturation when preterm delivery is anticipated. Emerging evidence also supports the use of low-dose aspirin for prevention in high-risk populations. Management approaches vary across different clinical settings, with resource-limited environments requiring adapted protocols. The review concludes that a multidisciplinary approach, early identification of at-risk patients, and individualized therapeutic strategies are essential to reduce adverse maternal and fetal outcomes associated with preeclampsia and eclampsia.]]>
Copyrights © 2026
